Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:activeIngredient |
gptkb:brexucabtagene_autoleucel
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XL10
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:drugClass |
immunotherapy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tecartus (2020)
|
| gptkbp:indication |
gptkb:mantle_cell_lymphoma
leukemia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Kite_Pharma
|
| gptkbp:mechanismOfAction |
CD19-directed genetically modified autologous T cell immunotherapy
|
| gptkbp:prescriptionRequired |
https://www.fda.gov/drugs/resources-information-approved-drugs/tecartus-brexucabtagene-autoleucel
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
cytokine release syndrome
neurological toxicities |
| gptkbp:target |
gptkb:CD19
|
| gptkbp:bfsParent |
gptkb:Kite_Pharma
|
| gptkbp:bfsLayer |
6
|